Lyra Therapeutics Inc. (LYRA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Lyra Therapeutics Inc. (LYRA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.18

-0.01 (-4.86%)

At close: Jan 15, 2025, 12:01 PM

undefined% (undefined)

Bid	0.18
Market Cap	12.04M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.49
PE Ratio (ttm)	-0.12
Forward PE	n/a
Analyst	Hold

Ask	0.19
Volume	1,221,790
Avg. Volume (20D)	2,055,311
Open	0.19
Previous Close	0.19
Day's Range	0.18 - 0.19
52-Week Range	0.16 - 6.79
Beta	undefined

About LYRA

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflam...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 1, 2020

Employees 88

Stock Exchange NASDAQ

Ticker Symbol LYRA

Website https://lyratherapeutics.com

Analyst Forecast

According to 5 analyst ratings, the average rating for LYRA stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 987.55% from the latest price.

Buy 40.00%

Hold 60.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Lyra Therapeutics Inc. is scheduled to release its earnings on Mar 20, 2025, during market hours.
Analysts project revenue of $204.80K, reflecting a 40.27% YoY growth and earnings per share of -0.13, making a -40.91% decrease YoY.

Why Price Moved

2 months ago · Source

-28.11%

Lyra Therapeutics shares are trading lower after t... Unlock content with Pro Subscription

8 months ago · Source

-19.46%

Lyra Therapeutics shares are trading lower on continued weakness after the company on Monday announced the ENLIGHTEN 1 trial did not meet its primary endpoint. Also, Jefferies downgraded the stock from Buy to Hold and lowered its price target from $10 to $0.5.

News

6 days ago · zacks.com

Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know

Lyra Therapeutics (LYRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

2 months ago · zacks.com

Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates

Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.27 per share a year ago.